Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.
Address
630 W GERMANTOWN PIKE
PLYMOUTH MEETING, PA 19462
Founded
2017
Number of Employees
246
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | - | - | - | - | $99,992 | - | $99,992 |
| Average Price | - | - | - | - | - | - | - | - | - | $30.72 | - | $30.72 |
| # Shares Purchased | - | - | - | - | - | - | - | - | - | 3,254,445 | - | 3,254,445 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | - | - | 23.7% | - | 23.7% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | - | - | 31.3% | - | 31.3% |
| Excess Total Return | - | - | - | - | - | - | - | - | - | -7.7% | - | -7.7% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | - | - | 64% | - | 57% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at HRMY make a trade.
Creating a free account takes less than one minute